Trial reportDiabetes & metabolism journal2023
Effect of Lactobacillus plantarum LMT1-48 on Body Fat in Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial.
Trial report in Diabetes & metabolism journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03759743 (a Randomised, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject), which is not on this map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
a Randomised, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy of probiotic supplementation for body weight management in overweight and obese adults: a meta-analysis of randomized controlled trials predominantly from East Asia.Frontiers in public health · 2026Pooled it
- ProbioticNarra J · 2025Pooled it
- The Role ofInternational journal of molecular sciences · 2024Pooled it
- Effects of a Plant-Based Multi-StrainNutrients · 2026Trial
- Trial
- Trial
- Plant-DerivedNutrients · 2022Trial
- Microbiome-mediated pharmacology of ginseng: Mechanistic insights into metabolic regulation and therapeutic potential.Journal of ginseng research · 2026Review
- Lactiplantibacillus plantarum: a Natural Ally in Combating Type 2 Diabetes Mellitus and Related Metabolic Disorders.Probiotics and antimicrobial proteins · 2026Review
- Genomic Scale Analysis Foresees Enteroprotective and Butyrogenic Properties in Brazilian Isolates of Lactiplantibacillus plantarum.Probiotics and antimicrobial proteins · 2025Article
- Targeting the Gut Microbiota in Pediatric Obesity: A Paradigm Shift in Prevention and Treatment? A Comprehensive Review.Nutrients · 2025Review
- Harnessing Probiotics: Exploring the Role of the Gut Microbiome in Combating Obesity.Probiotics and antimicrobial proteins · 2025Review
- The Effects of Probiotics Consumption on Blood Pressure, Lipid Profile, Glycemic Indices, and Inflammatory Parameters in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Food science & nutrition · 2025Review
- Microbiome, Potential Therapeutic Agents: New Players of Obesity Treatment.Journal of microbiology and biotechnology · 2025Review
- Strain-Specific Therapeutic Potential ofNutrients · 2025Article
- The Benefits and Applications ofIranian journal of public health · 2024Review
- Probiotics in reducing obesity by reconfiguring the gut microbiota.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Review
- Efficacy and Safety of WCFA19 (Journal of clinical medicine · 2024Article
- Microbial-Based Bioactive Compounds to Alleviate Inflammation in Obesity.Current issues in molecular biology · 2024Review
- The Effect ofMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe investigated whether Lactobacillus plantarum strain LMT1-48, isolated from Korean fermented foods and newborn feces, is a suitable probiotic supplement to treat overweight subjects.
methodsIn this randomized, double-blind, placebo-controlled clinical trial, 100 volunteers with a body mass index of 25 to 30 kg/m2 were assigned randomly (1:1) to receive 2×1010 colony forming units of LMT1-48 or to a placebo treatment group. Body composition was measured by dual-energy X-ray absorptiometry, and abdominal visceral fat area (VFA) and subcutaneous fat area were measured by computed tomography scanning. Changes in body fat, VFA, anthropometric parameters, and biomarkers were compared between the two treatment groups (ClinicalTrials.gov number: NCT03759743).
resultsAfter 12 weeks of treatment, the body weight decreased significantly from 76.6±9.4 to 75.7±9.2 kg in the LMT1-48 group but did not change in the placebo group (P=0.022 between groups). A similar pattern was found in abdominal VFA between the two groups (P=0.041). Serum insulin levels, the corresponding homeostasis model assessment of insulin resistance, and leptin levels decreased in the LMT1-48 group but increased in the placebo group (all P<0.05). Decrease in body weight and body mass index by treatment with LMT1-48 was correlated with increase in Lactobacillus levels significantly. LMT1-48 also increased Oscillibacter levels significantly, which were negatively correlated with triglyceride and alanine transaminase levels.
conclusionAdministration of LMT1-48 decreased body weight, abdominal VFA, insulin resistance, and leptin levels in these subjects with overweight, suggesting its anti-obesogenic therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.